ALKALINE PHOSPHATASE REAGENT SET
For the
Direct Colorimetric determination of alkaline phosphatase
in human serum.
INTRODUCTION
Distributed in almost every tissue of the body, serum alkaline phosphatase (ALP) levels are of interest in the
diagnosis of hepatobiliary
disorder and bone disease.1 Most
of the ALP in normal adults serum is from the liver or biliary
tract.2 Normal alkaline phosphatase levels are age dependent, and levels are elevated during periods of active
bone growth. Moderate elevations of ALP
(not involving the liver or bone) may be attributed to Hodgins'
disease, congestive heart failure, and abdominal bacterial infections.3 Elevations also occur in the
third trimester of pregnancy.
Earlier methods were based on
the measurement of phosphate liberated by the action of the enzyme on a beta-glycerolphosphate substrate or on the measurement of phenol
liberated from disodium phenyl phosphate
substrate. Many of these substrates are
unstable in solution and need to be prepared fresh daily. The substrate developed by
PRINCIPLE
The alkaline phosphatase acts upon the AMP-buffered sodium thymolphthaIein
monophosphate.
The addition of an alkaline reagent stops enzyme activity and
simultaneously develops a blue chromogen which is
measured photometrically.
REAGENT COMPOSITION
Alkaline Phosphatase
Substrate: 3.6 mM,
Sodium Thymolph- thalein Monophosphate in 0.2 M 2-Amino-2-Methyl-l-Propanol
buffer. Magnesium Chloride l.0 mM, wetting agent, inactive ingredients, preservatives; pH
10.2 ± 0.1.
WARNING: MAY CAUSE SKIN IRRITATION.
Alkaline Phosphatase
Color Developer: 0.1 M Sodium Hydroxide,
0.1 M Sodium Carbonate.
DANGER: CAUSES BURNS.
Alkaline Phosphatase
Standard: Thymolphthalein in n-Propanol
0.5 mM/L. Equivalent to 50 U/L enzyme activity when used according to the Alkaline Phosphatase Procedure.
WARNINGS AND PRECAUTIONS:
1. For
in vitro diagnostic use.
CAUTION: In vitro diagnostic reagents may be
hazardous.
Handle in accordance with good laboratory
procedures
which dictate
avoiding ingestion, and eye or skin contact.
2. Specimens should be considered infectious and handled
appropriately.
3. In
case of contact with Alkaline Phosphatase Color
Developer, wash with copious amounts of water. Do not ingest.
STORAGE AND STABILITY
Store reagent set at 2 - 8°C
(refrigerated)
REAGENT DETERIORATION
1. The Alkaline Phosphatase Substrate
should be a clear amber solution. A
precipitation or blue-green color would indicate deterioration.
2. The Alkaline Color Developer should be a clear colorless solution.
3. Failure of the Alkaline Phosphatase
Standard to achieve assayed values of freshly prepared control sera would indicate
deterioration.
SPECIMEN COLLECTION
Unhemolyzed serum is the preferred
sample. Heparinized
plasma may also be used. Oxalate, fluoride and EDTA inhibit ALP, so are
unsuitable as anticoagulants.5
Samples should be kept cold and assayed as soon as possible
after collection. A timed routine for sample collection and analysis should be
established in each laboratory because ALP levels in serum or plasma, or in
reconstituted control serum, rise significantly when stored at
2 - 8°C or
at room temperature.
INTERFERING SUBSTANCES
EDTA, citrate, fluoride and
oxalate inhibit ALP. Young, et al. give a list of drugs and other substances
which may interfere with the determination of ALP activity.6
MATERIALS REQUIRED BUT NOT
PROVIDED
1. Pipetting devices.
2. Test tubes/rack.
3. Timer.
4. Spectrophotometer with a
temperature controlled cuvette.
5. Heating bath/ block.
PROCEDURE (MANUAL)
1. For each
sample, dispense 0.5 rnL of Alkaline Phosphatase
Substrate into labeled test
tubes and equilibrate to 37°C for three (3) minutes.
2. At timed intervals, add 0.05 mL (50 µl) of each standard,
control, and sample to its respective test tube. Mix gently.  Use
deionized water as sample for Reagent Blank.
3. Incubate for exactly ten (10)
minutes at 37°C.
4. Follow
the same sequence as in Step 2 add 2.5 mL Alkaline
Phosphatase
Color Developer at timed intervals. Mix
well.
5. Set the wavelength of the
spectrophotometer at 590 nm.  Zero
with Reagent Blank. (Wavelength range:580-630)
6. Read and record absorbance of
samples.
* USE TC - MUTI PURPOSE CALIBRATOR TO
REPLACE STANDARD.
NOTE 1. If
the activity is greater than 100 IU/L repeat the
assay with test
specimen diluted two (2) fold with
normal
saline and multiply the dilutes test results
by two (2).
2. The final colored product is
stable for 60 minutes at
controlled
room temperature (15 - 30°C).
CALCULATION
Abs of Unk. x Value of Std.
(IU/L) = Unk. (lU/L)
Abs of Std.
Example: Unknown
Absorbance = 0.224
Standard
Absorbance = 0.313
Standard
Value = 50 IU/L
0.224 x 50
IU/L = 35.7 IU/L
0.313
PROCEDURAL LIMITATIONS:
This methodology measures
total ALP irrespective of tissue or organ of origin. Further tests may be necessary to assist in
differential diagnosis.
QUALITY CONTROL
It is recommended that
controls be included in each set of assays. Commercially available control
material with established ALP activity may be used for quality control. The
assigned value of the control material must be confirmed by the chosen
application. Failure to obtain the proper range of values in the assay of
control material may indicate either reagent
deterioration, instrument malfunction, or procedural errors.
EXPECTED VALUES
Adults:
9-35 IU/L at 37°C. Children have a higher normal value. It is strongly
suggested that each laboratory establish its own normal range.7
PERFORMANCE CHARACTERISTICS
l. Linearity:
100 IU/L
2. Sensitivity: Based on instrument resolution of A = 0.001, the present
procedure has a sensitivity of 0. 16 IU/L.
3. Comparison: A study performed between the present procedure
and one commercial product
resulted in a coefficient of
correlation of 0.99 with a regression of y = 1.02x +
0.75.
4. Precision studies
Within
Run
Mean (IU/L) S.D. C.V.
34.8 1.1 3.1%
85.6 2.6 3.1%
Run
to Run
Mean (]U/L) S.D. C.V.
34.9 1.5 4.2%
84.3 2.6 3.1%
REFERENCES
1. Kochmar, J.F., and Moss, D.W.: Fundamentals
of Clinical
Chemistry, N.W. Tietz (ed), p. 604, W.B. Saunders and
Company, Philadelphia, PA (1976).
2. Kaplan, M.M., and Righetti, A.: J. Clin. Inv. 34:126
(1955).
3. Kaplan, M.M.:
4.
5. Demetrious, J.A., et al.: Enzymes in Clinical Chemistry
Principles and Technics, 2nd Ed. Hagerstown (MD), Harper and Row 927 (1974).
6. Young, D.S., et al: Clin. Chem 21:5 (1975).
7. Tietz,
N.: Fundamentals of Clinical Chemistry
602 - 609 (1976).
Date revised: 6/95